Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder

Cancer

Volumn 78, Issue 8, 1996, Pages 1762-1774

  Shiina, Hiroaki ^a   Igawa, Mikio ^a   Nagami, Haruhiko ^a   Yagi, Hiroshi ^a   Urakami, Shinji ^a   Yoneda, Tatsuaki ^a   Shirakawa, Hiroki ^a   Ishibe, Tomoyuki ^a   Kawanishi, Masahiro ^b  

^a SHIMANE UNIVERSITY   (Japan)

^b Hiroshima Mitsubishi Hospital   (Japan)

Author keywords

bladder; expression; nm23 protein; nuclear DNA content; p53 protein; proliferating cell nuclear antigen; transitional cell carcinoma

Indexed keywords

CELL NUCLEUS DNA; CYCLINE; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER STAGING; COMPUTER ANALYSIS; CONTROLLED STUDY; DNA CONTENT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NUCLEOSIDE-DIPHOSPHATE KINASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0029738970     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961015)78:8<1762::AID-CNCR17>3.0.CO;2-W     Document Type: Article

References (50)

1. Bravo R, Celis JE. A search for differential polypeptide synthesis throughout the cell cycle of He La cells. J Cell Biol 1980;84:795-802.
2. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57: 1083-93.
3. Prehlich G, Kostura M, Marshak KDR, Matthews MB, Stillman B. The cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro. Nature 1987;326:471-5.
4. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase delta. Nature 1987;326:515-7.
5. Celis JE, Celis A. Cell cycle dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells:subdivision of S phase. Proc Natl Acad Sci USA 1985;82:3262-6.
6. Lipponen PK, Eskelinen MJ. Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value. Br J Cancer 1992;66:171-6.
7. Vogelstein B, Kinzler K. p53 function and dysfunction. Cell 1992;70:523-6.
8. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
9. Dalbagni G, Saez GT, Oliva MR, Pellicer A, Reuter VE, Fair WR, et al. P53 mutations in bladder cancer: correlation between immunohistochemistry (IHC), single strand conformation polymorphism (SSCP) and sequencing. J Urol 1993;49:238A.
10. Lipponen PK. Expression of nuclear oncoprotein p53 in transitional cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-70.
11. Sarkis AS, Dalbagni G, Cordon-Carbo C, Zhang Z-F, Sheinfeld J, Fair FR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma:a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
12. Mercer WE, Shields MT, Lin D, Appella E, Ullrich SJ. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci USA 1991; 88:1958-62.
13. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-4.
14. Gilles A-M, Presecan E, Vonica A, Lascu I. Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme. J Biol Chem 1991;266:8784-9.
15. von Dobeln U. Nucleoside diphosphate kinase activity associated with ribonucleotide reductase. Biochem Biophys Res Commun 1976;72:1160-8.
16. Igawa M, Rukstalis DB, Tanabe T, Chodak GW. High levels of nm23 expression are related to cell proliferation in human prostate cancer. Cancer Res 1994;54:1313-8.
17. Tomasi TB. Oncogenes and cancer. In: Fenoglio-Beiser CM, Weinstein RS, Kaufman N, editors. New concepts in neoplasia as applied to diagnostic pathology. Volume 27. Baltimore: Williams and Wilkins, 1986:59-90.
18. Oljans PJ, Tanke HJ. Flow cytometric analysis of DNA content in bladder cancer:prognostic value of the DNA-index with respect to early tumour recurrence in G2 tumours. World J Urol 1986;4:205-10.
19. Blomjous CEM, Schipper NW, Baak JPA, van Galen EM, de Voogt HJ, Meijer CJLM. Retrospective study of prognostic importance of DNA flow cytometry of urinary bladder transitional cell carcinoma. J Clin Pathol 1988;41:21-5.
20. Shaaban AA, Tribukait B, El-Bedeiwy AA, Ghoneim MA. Prediction of lymph node metastases in bladder carcinoma with deoxyribonucleic acid flow cytometry. J Urol 1990;144:884-7.
21. Auffermann W, Urquardt M, Rübben H, Wohltmann D, Böcking A. DNA grading of urothelial carcinoma of the bladder. Anticancer Res 1986;6:27-32.
22. Schapers RFM, Ploem-Zaaijer JJ, Pauwels RPE, Smeets AWGB, van Den Brandt PA, Tanke HJ, et al. Image cytometric DNA analysis in transitional cell carcinoma of the bladder. Cancer 1993;72:182-9.
23. Böcking A, Adler CP, Common HH, Hilgarth M, Granzen B, Auffermann W. Algorithm for DNA-cytophotometric diagnosis and grading of malignancy. Anal Quant Cytol Histol 1984;6:1-8.
24. Tubiana M, Courdi A. Cell proliferation kinetics in human solid tumors:relation to probability of dissemination and long-term survival. Radiother Oncol 1989;15:1-18.
25. Hermanek P, Scheibe O, Spiessl B, Wagner G. TNM Klassifikation maligner Tumoren, UICC. New York: Springer, 1987.
26. Mostofi FK, Sobin LH, Torloni H. International histological typing of urinary bladder tumours. Geneva: World Health Organization, 1973.
27. Karamitopoulou E, Perentes E, Diamantis I. p53 protein expression in central nervous system tumours: an immunohistochemical study with CMI polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol (Berl) 1993;85:611-6.
28. Baas IO, Mulder J-WR, Offerhaus GLA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
29. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992;151:237-44.
30. Bacus JW, Grade LJ. Optical microscope system for standardized cell measurements and analyses. Appl Optics 1987;26:3280-93.
31. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-81.
32. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:248-75.
33. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995;71:201-5.
34. Sidransky D, von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53-gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
35. Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
36. Werness BA, Levine AJ, Howley PM. Association of human papilloma virus type 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
37. Hall PA, McKee PH, Du P, Menage H, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993;8:203-7.
38. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18.
39. Wynford-Thomas D. p53 in tumor pathology:can we trust immunocytochemistry? J Pathol 1992;166:329-30.
40. Keim D, Hailat N, Melhem R, Zhu XX, Lascu I, Veron M, et al. Proliferation-related expression of p19/nm23 nucleoside diphosphate kinase. J Clin Invest 1992;89:919-24.
41. Hout M, Steeg PS, Willson JK, Markowitz SD. Induction of nm23 gene expression in human colonic neoplasm and equal expression in colon tumours of high and low metastatic potential. J Natl Cancer Inst 1991;83:712-6.
42. Wang L, Patel U, Ghosh L, Chen H-C, Banerjee S. Mutation in nm23 gene is associated with metastasis in colorectal cancer. Cancer Res 1993;53:717-20.
43. Chang CL, Zhu XX, Thoraval DH, Ungar D, Rawwas J, Hora N, et al. nm23 H-1 mutation in neuroblastoma. Nature 1994;370:335-6.
44. Hemstreet GP, Rollins S, Jones P, Rao JY, Hurst RE, Bonner RB, et al. Identification of a high risk subgroup of grade 1 transitional cell carcinoma using image analysis based deoxyribonucleic acid ploidy analysis of tumor tissue. J Urol 1991;146:1525-9.
45. Lipponen PK. Histological and quantitative prognostic factors in transitional cell bladder cancer treated by cystectomy. Anticancer Res 1992;12:1527-32.
46. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120-5.
47. Hepburn PJ, Glynne-Jones E, Goddard L, Gee JMW, Harper ME. Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA. Histochem J 1995; 27:196-203.
48. Norton AJ. Microwave oven heating for antigen unmasking in routinely processed tissue sections. J Pathol 1993;171:79-80.
49. Hall PA, Levison DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections:an index ofcell proliferation with evidence of deregulated expressionin some neoplasms. J Pathol 1990;162:285-94.
50. Harper ME, Glynne-Jones E, Goddard L, Wilson DW, Matenhelia SS, Conn IG, et al. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate 1992;20:243-53.